Buy Rating for Structure Therapeutics: Aleniglipron’s Market Potential and Acquisition Appeal

H.C. Wainwright analyst Ananda Ghosh has maintained their bullish stance on GPCR stock, giving a Buy rating on September 18.

Ananda Ghosh has given his Buy rating due to a combination of factors that highlight the potential of Structure Therapeutics’ aleniglipron. The recent data from the ATTAIN-1 trial of orforglipron, which showed significant weight loss and cardiometabolic benefits, also revealed some limitations such as gastrointestinal issues and a gap in efficacy compared to injectable treatments. In contrast, aleniglipron is noted for its early weight loss results, excellent gastrointestinal tolerability, and convenient oral dosing, which positions it favorably in the market.
Moreover, the recent Pfizer-Metsera deal underscores the growing interest in oral incretins, especially those with a differentiated safety and tolerability profile. This context suggests that aleniglipron, with its promising Phase 2 program and strategic positioning, could be an attractive acquisition target. The ongoing development and potential combination programs further enhance its appeal, supporting Ghosh’s optimistic outlook and Buy rating for the stock.

In another report released on September 18, LifeSci Capital also maintained a Buy rating on the stock with a $75.00 price target.